BeiGene, EUSA Pharma announce development deal for SYLVANT, QARZIBA
EUSA Pharma and BeiGene announced that they have entered into an exclusive development and commercialization agreement for the orphan biologic products SYLVANT and QARZIBA in Greater China. Under the terms of the agreement, EUSA has granted BeiGene exclusive rights to SYLVANT in Greater China and to QARZIBA in mainland China. Under the agreement, BeiGene will fund and undertake all clinical development and regulatory submissions in the territories, and will launch and commercialize both products once approved. EUSA will receive an upfront payment and be eligible to receive payments upon the achievement of regulatory and commercial milestones up to a total of $160 million. EUSA will also be eligible to receive tiered royalties on future product sales.